Edit Entry

David J. Bzik, Ph.D.

Title(s):
Professor of Microbiology and Immunology

Department(s):
Microbiology and Immunology

Education:
Pennsylvania State University, PHD 1983
Pennsylvania State University, MS 1980
Lehigh University, BA 1977

Dr. Bzik received his undergraduate degree in Biology from Lehigh University in 1977, and his Ph.D. degree in Biophysics from the Pennsylvania State University in 1983. After postdoctoral work as a European Molecular Biology Organization long-term fellow at the MRC Virology Unit at Glasgow University, Dr. Bzik joined the faculty of the Department of Microbiology at Dartmouth Medical School in 1988.

Programs:
Molecular and Cellular Biology Graduate Programs

Websites:
http://dms.dartmouth.edu/microbio/
http://dms.dartmouth.edu/immuno/
http://www.dartmouth.edu/~mcb/

Contact Information:

Dartmouth Medical School
Borwell Research Bldg. HB 7556
1 Medical Center Drive
Lebanon NH 03756

Phone: 603-650-7951
Fax: 603-650-6223
Email: David.J.Bzik@Dartmouth.EDU


Professional Interests:

GENETIC ANALYSIS OF HOST-PARASITE INTERACTIONS

Our major research interests involve the molecular mechanisms of parasite pathogenesis. We focus on the protozoan parasites Toxoplasma gondii and Plasmodium falciparum. These apicomplexan parasites represent a paradigm of obligate intracellular infectious disease agents. Plasmodium falciparum causes a devastating form of human malaria which infects vast numbers of people and causes significant morbidity (adults and children) and mortality (mainly children). Toxoplasma gondii infection causes severe congenital defects in infants and death in HIV/AIDS patients. Current research projects include the following: developmental regulation of parasite virulence factors; identification of new parasite virulence determinants; development of new tools to facilitate genetic analysis of parasite pathogens; mechanisms, regulation and drug discovery in pyrimidine and purine acquisition pathways; design of vaccine components based on secreted antigens; novel parasite enzymes: mechanisms, regulation and drug discovery; creation and evaluation of live attenuated parasite vaccines; taming and targeting parasites for cancer gene therapy. Visit the Molecular Pathogenesis Website.


Selected Publications:

 

Mouveaux T, Oria G, Werkmeister E, Slomianny C, Fox BA, Bzik DJ, Tomavo S
Nuclear glycolytic enzyme enolase of Toxoplasma gondii functions as a transcriptional regulator.
PLoS One 2014; 9(8):e105820
PMID: 25153525

Tomita T, Bzik DJ, Ma YF, Fox BA, Markillie LM, Taylor RC, Kim K, Weiss LM
The Toxoplasma gondii cyst wall protein CST1 is critical for cyst wall integrity and promotes bradyzoite persistence.
PLoS Pathog 2013; 9(12):e1003823
PMID: 24385904

Fox BA, Sanders KL, Bzik DJ
Non-replicating Toxoplasma gondii reverses tumor-associated immunosuppression.
Oncoimmunology 2013 Nov 1; 2(11):e26296
PMID: 24353916

Patil V, Zhao Y, Shah S, Fox BA, Rommereim LM, Bzik DJ, Yap GS
Co-existence of classical and alternative activation programs in macrophages responding to Toxoplasma gondii.
Int J Parasitol 2014 Feb; 44(2):161-4
PMID: 24083945

Fox BA, Sanders KL, Chen S, Bzik DJ
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.
Trends Parasitol 2013 Sep; 29(9):431-7
PMID: 23928100

Rommereim LM, Hortua Triana MA, Falla A, Sanders KL, Guevara RB, Bzik DJ, Fox BA
Genetic manipulation in Δku80 strains for functional genomic analysis of Toxoplasma gondii.
J Vis Exp 2013 Jul 12; (77):e50598
PMID: 23892917

Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S, Bzik DJ
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.
Cancer Res 2013 Jul 1; 73(13):3842-51
PMID: 23704211

Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.
J Immunol 2013 Jan 1; 190(1):469-78
PMID: 23225891

Fox BA, Falla A, Rommereim LM, Tomita T, Gigley JP, Mercier C, Cesbron-Delauw MF, Weiss LM, Bzik DJ
Type II Toxoplasma gondii KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection.
Eukaryot Cell 2011 Sep; 10(9):1193-206
PMID: 21531875

Fox BA, Bzik DJ
Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii.
Infect Immun 2010 Sep; 78(9):3744-52
PMID: 20605980